VIE

Viela Bio Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

42.02
+1.21
+2.97%
After Hours: 42.02 0 0.00% 16:01 07/15 EDT
OPEN
42.55
PREV CLOSE
40.81
HIGH
43.00
LOW
40.11
VOLUME
280.61K
TURNOVER
--
52 WEEK HIGH
70.66
52 WEEK LOW
18.20
MARKET CAP
2.29B
P/E (TTM)
-16.4842
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 7 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average VIE stock price target is 63.17 with a high estimate of 78.00 and a low estimate of 49.00.

EPS

VIE News

More
Goldman Sachs Upgrades Viela Bio to Neutral, Raises Price Target to $49
Goldman Sachs analyst Paul Choi upgrades Viela Bio (NASDAQ:VIE) from Sell to Neutral and raises the price target from $48 to $49.
Benzinga · 10h ago
Attention Biotech Investors: Mark Your Calendar For These July PDUFA Dates
The busy calendar of June proved positive for drug approvals, with most scheduled events producing positive outcomes. New molecular entity, or NME, approval for the month totaled two, taking the total NME approvals for the year to 24.
Benzinga · 07/01 14:05
3 Ultra-High-Growth Biopharma Stocks to Grab Now
MotleyFool.com · 06/19 10:25
Viela Bio Gets Approval And Other News: The Good, Bad And Ugly Of Biopharma
Seeking Alpha - Article · 06/16 09:13
The Week Ahead In Biotech: FDA Decisions In The Cards For Merck, Epizyme, Evoke And Ultragenyx
Biotech stocks came under pressure along with the broader market in the week ended June 12, as a worsening pandemic situation and its impact on the economy led to an across-the-board sell-off in the global markets.
Benzinga · 06/14 14:20
Hedge Funds Cautiously Watching Viela Bio, Inc. (VIE)
In this article we will check out the progression of hedge fund sentiment towards Viela Bio, Inc. (NASDAQ:VIE) and determine whether it is a good investment right now. We at Insider Monkey like to examine what billionaires and hedge funds think of a company be
Insider Monkey · 06/12 18:07
FDA approves Viela's rare disease treatment, analysts predict $500 million in sales
MarketWatch · 06/12 13:45
HC Wainwright & Co. Maintains Buy on Viela Bio, Raises Price Target to $76
HC Wainwright & Co. maintains Viela Bio (NASDAQ:VIE) with a Buy and raises the price target from $70 to $76.
Benzinga · 06/12 10:28

Industry

Biotechnology & Medical Research
+1.38%
Pharmaceuticals & Medical Research
+1.63%

Hot Stocks

Symbol
Price
%Change

About VIE

Viela Bio Inc. is a clinical-stage biotechnology company. The Company is focused on developing treatments for severe inflammation and autoimmune diseases. Its product pipeline includes Inebilizumab, VIB4920 and VIB7734. Inebilizumab is a humanized mAb that binds to and depletes CD19+ B cells including plasmablasts and plasma cells. VIB4920 is a fusion protein designed to bind to CD40 ligand (CD40L) on activated T cells, blocking the interaction with CD40 expressed on B cells and preventing them from differentiating into plasma cells and memory B cells. VIB7734 is a treatment for autoimmune and related inflammatory diseases.
More

Webull offers kinds of Viela Bio Inc stock information, including NASDAQ:VIE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VIE stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading VIE stock methods without spending real money on the virtual paper trading platform.